Soft Tissue Necrosis in Head and Neck Cancer Patients After Transoral Robotic Surgery or Wide Excision With Primary Closure Followed by Radiation Therapy

Lee Yun Hee, MD, Yeon Sil Kim, MD, Mi Joo Chung, MD, Mina Yu, MD, So Lyung Jung, MD, Je Ryung Yoo, MD, Youn Soo Lee, MD, Min Sik Kim, MD, Dong Il Sun, MD, and Jin Hyung Kang, MD

Abstract: Risk factors were evaluated for surgical bed soft tissue necrosis (STN) in head and neck cancer patients treated with postoperative radiation therapy (PORT) after transoral robotic surgery (TORS) or wide excision with primary closure. Sixty-seven patients were evaluated. STN was defined as ulceration and necrosis of the surgical bed or persistently unhealed high-grade acute mucositis with pain after PORT. The median RT dose of primary site was 63.6 Gy (range, 45.6–71.5 Gy) with 2 Gy/fx (range, 1.8–2.2 Gy/fx). Total 41 patients (61.2%) were treated with concurrent chemoradiotherapy. The median follow-up period was 26 months. STN was diagnosed in 13 patients (19.4%). Most of the patients were treated with oral steroids, antibiotics, and analgesics and the lesions were eventually improved (median of 6 months after PORT). STN did not influence local control. A depth of invasion (DOI > 1.4 cm, odds ratio [OR] 14.04, \( p = 0.004 \)) and maximum dose/fraction (\( CTV_{p_{\text{max}}}/fx > 2.3 \text{ Gy} \), OR 6.090, \( p = 0.054 \)) were related to STN. The 12 (23.5%) of 51 oropharyngeal cancer patients presented STN, and the risk factors were DOI > 1.2 cm (OR 21.499, \( p = 0.005 \)), \( CTV_{p_{\text{max}}}/fx > 2.3 \text{ Gy} \) (OR 12.972, \( p = 0.021 \)) and grade 3 acute mucositis (OR 10.537, \( p = 0.054 \)) were related to STN. The 12 (23.5%) of 51 oropharyngeal cancer patients presented STN, and the risk factors were DOI > 1.2 cm (OR 21.499, \( p = 0.005 \)), \( CTV_{p_{\text{max}}}/fx > 2.3 \text{ Gy} \) (OR 12.972, \( p = 0.021 \)) and grade 3 acute mucositis (OR 10.537, \( p = 0.054 \)). Patients treated with TORS or WE with primary closure followed by PORT had a high risk of surgical bed STN. STN risk factors included DOI (>1.2–1.4 cm) and \( CTV_{p_{\text{max}}}/fx > 2.3 \text{ Gy} \). Radiation therapy after TORS must be carefully designed to prevent STN.

(Medicine 95(9):e2852)

Abbreviations: CCRT = concurrent chemoradiotherapy, CLE = consequential late effect, \( CTV_p \) = clinical target volume of primary tumor bed, \( CTV_{p_{\text{max}}} \) = maximum total dose of \( CTV_p \), \( CTV_{p_{\text{mean}}} \) = mean dose of \( CTV_p \), \( CTV_{p_{\text{mean}}}/fx \) = fraction size of \( CTV_{p_{\text{mean}}} \), \( CTV_{p_{\text{max}}}/fx \) = fraction size of \( CTV_{p_{\text{max}}} \), DOI = depth of invasion, IMRT = intensity modulated radiotherapy, PORT = postoperative radiation therapy, RT = radiotherapy, STN = soft tissue necrosis, TORS = transoral robotic surgery, WE = wide excision.

INTRODUCTION

W

With advances in surgical and radiotherapy (RT) techniques, the oncologic and functional outcomes of head and neck cancer patients are improving. Organ and function preservation with a lesser treatment morbidity is an important goal of treatment plan. Several studies have shown the feasibility and safety and promising oncologic results of using transoral robotic surgery (TORS) since its introduction as a minimally invasive technique by Drs. Weinstein and O’Malley in 2006.3 TORS has been increasingly used to preserve patient functions2,4 and the most commonly applied anatomic site is oropharynx. With the favorable outcomes reported, the indication of TORS has been extended to laryngeal and hypopharyngeal cancer.5 Swallowing and speech functions have improved and surgical morbidities or cosmetic deformities have decreased in patients treated with TORS. According to surgical pathology, adjuvant RT or concurrent chemoradiotherapy (CCRT) after TORS is recommended to improve local control and overall survival. However, the treatment outcome and toxicity of adjuvant RT or CCRT after TORS are not well described.6 There is growing concern related to the complications after TORS followed by RT and the morbidities are not well documented. Several studies have reported unexpected delays in wound healing and STN related to adjuvant RT, and suggested contraindications related to TORS.7,9

Radiation-induced mucositis is resolved through the regeneration process, which requires proliferative stem cells and vascular and connective supplies.10 Disruptions to the lymphovascular supply and injuries to connective tissue along with the reduced repopulation of stem cells in surgical beds might be induced by TORS or wide excision (WE) without reconstructive surgery. This could result in unexpected complications after postoperative radiation therapy (PORT).

We evaluated the frequency and risk factors for surgical bed soft tissue necrosis (STN) in head and neck cancer patients treated with PORT after TORS or WE with primary closure. We attempted to determine quantitative values related to STN, including tumor and dosimetric factors.

PATIENTS AND METHODS

We retrospectively reviewed patients treated with TORS or WE and PORT for head and neck cancer between 2008 and 2014 at Seoul St. Mary’s hospital. Adjuvant treatment was
RESULTS

The median follow-up period was 26 months (range, 4–74 months), and the median age was 59 years old (range, 35–89 years old). Surgery types were as follows: TORS (30 patients) and WE with primary closure without reconstructive surgery (37 patients). Patients who were undergoing flap reconstruction were not included in this study. A total of 41 patients (61.2%) were treated with CCRT, and the chemotherapy regimens consisted of fluorouracil/cisplatin (34 of 41) and cisplatin (7 of 41). RT was intentionally delivered to primary tumor bed in 57 patients, and another 10 patients received radiation on the regional neck lymphatics only. However, the adjacent mucosa was indirectly irradiated. The median RT dose of the primary site was 63.6 Gy (range, 45–67.15 Gy) with 2 Gy/fx (range 1.8–2.2 Gy/fx). Indications for adjuvant RT were extracapsular extension (41.8%), positive margin (26.9%), close margin (4.5%), perineural invasion (6%), lymphovascular invasion (50.7%), and stage pN2b, pN2c, pN3 (76.1%) and T3–4 (14.9%).

A total of 13 patients (19.4%) had a diagnosis of STN. In 7 patients, STN developed after recovery from acute mucositis, and the median time interval from RT completion was 2.7 months (range, 1.7–5.3 month). The remaining 6 patients showed sustained high-grade mucositis in the resection bed of the primary lesion. The NPL showed the ulceration or necrosis of the mucosa in the resection bed of the primary lesion (Figure 1). Magnetic resonance imaging (MRI) showed that 7 patients had mucosal thickening and enhancement in the surgical bed that requiring differentiation between RT related changes and tumor recurrence. The remaining 6 patients did not present abnormal enhancement. The positron emission tomography/computed tomography (PET/CT) were evaluated showing the localized increased fluorodeoxyglucose uptake. The maximum standard uptake value was median 4.1 (range, 2.3–8.6), and the uptake was regressed in the follow-up PET/CT.

Two patients were evaluated through a biopsy of the ulcerative lesion to differentiate the tumor recurrence; however, necrotic tissue and several atypical cells with reactive atypia were found. Most of the patients were treated with oral steroids, antibiotics, and analgesics. Eight patients complained of severe pain at the primary surgical bed, and narcotic analgesics were required for pain control. One patient had to be treated with debridement of the tumor bed, and 1 patient was treated with steroid injection into the necrosis bed. STN lesions were eventually resolved at a median of 6 months (range, 2.5–14 months) after PORT. Local recurrence was not observed in STN patients. The 3-year LCR was 92.7%, 100%, and 91.0% for all patients, STN patients, and non-STN patients, respectively. The 3-year OSR was 74.9% for all patients (Figure 2).

Risk Factors for STN for All Patients

The frequency of STN according to the primary lesion was as follows: oropharynx (12 of 51 patients, 23.5%), hypopharynx (1 of 5, 20%), larynx (0 of 9, 0%), and oral cavity (0 of 2, 0%). The patient and treatment characteristics are shown in Table 1. Comorbidities (P = 0.013), DOI (P = 0.003), and grade 3 acute mucositis (P = 0.007) were significantly associated with STN occurrence. The comorbidities were as follows: hypertension (HTN) in 26 patients, diabetes in 8 patients, other cancer in 8 patients, liver disease in 7 patients, lung disease in 2 patients, coronary artery disease in 2 patients, cerebrovascular disease in 1 patient, kidney disease in 1 patient, and thyroid disease in 1 patient. Sex, age, smoking status, pathologic T stage, tumor...
size, and concurrent chemoradiotherapy did not present significant differences between the STN and non-STN patients. As for the dosimetric factors, a higher maximum dose/fraction (CTVpmax/fx) was significantly associated with STN occurrence (STN vs non-STN, 2.3 Gy vs 2.19, \( P = 0.038 \)). The time interval between surgery and RT commencement, RT duration, total treatment duration, RT modality, CTVp volume, CTVp mean, CTVpmax, CTVp mean BED (10), and CTVp max BED (10) had no influence on the occurrence of STN.

To determine the cut-off values for the DOI and CTVpmax/fx, an ROC curve was generated and Youden index was calculated. For the DOI, the AUC value of the ROC curve was 0.773 (95% confidence interval [CI] = 0.641–0.874, \( P = 0.0021 \)) and the cut-off value according to Youden index was the 1.4 cm (sensitivity 61.54%, specificity 93.02%). For the CTVpmax/fx, the AUC values was 0.718 (95% CI = 0.594–0.822, \( P = 0.0122 \)) and cut-off value was 2.3 Gy/fx (sensitivity 50.0%, specificity 87.04%). ROC curves of DOI and CTVpmax/fx are described in Figure 3A. In addition, DOI values >1.4 cm, and CTVpmax/fx values >2.3 Gy/fx had significantly associated with STN occurrence in the univariate analysis (Table 2).

Significant factors (\( P \)-value of <0.10) in the univariate analysis and the cut-off values from the ROC curve were included in the multivariate analysis. Comorbidities, acute grade 3 mucositis, stage pT2–3, DOI, DOI >1.4 cm, CTVpmax/fx and CTVpmax/fx >2.3 Gy/fx were included in the multivariate logistic regression analysis. DOI >1.4 cm (odds ratio [OR] 14.04, \( P = 0.004 \)) and CTVpmax/fx >2.3 Gy/fx (OR 6.344, \( P = 0.043 \)) were predictors for STN occurrence in all patients. Acute grade 3 mucositis presented a tendency of significance (OR 6.090, \( P = 0.054 \)). The results of the multivariate analysis are shown in Table 3.

**Risk Factors for STN in Oropharyngeal Cancer Patients**

Oropharyngeal cancer patients (51 patients) were analyzed separately. A total of 11 patients (21.6%) developed STN. The
significant predictors for STN from the univariate analysis were comorbidities ($P = 0.034$), DOI ($P = 0.002$), acute grade 3 mucositis ($P = 0.044$), and $CTV_{p,max}/fx$ ($P = 0.028$). HPV status was not associated with STN occurrence (Table 4). For the DOI, the AUC value in the ROC curve was 0.810 (95% CI = 0.659–0.914, $P = 0.0002$) and the cut-off value according to Youden index was >1.2 cm (sensitivity 75%, specificity 85.33%). For the $CTV_{p,max}/fx$, the AUC value was 0.735 (95% CI = 0.561–0.908, $P = 0.023$) and cut-off value was 2.3 Gy/fx (sensitivity 54.5%, specificity 86.7%). For the tumor size, the AUC value were 0.667 (95% CI = 0.514–0.797, $P = 0.056$) and cut-off value was >2.5 cm (sensitivity 58.33%, specificity 77.14%). For $CTV_{p,max}$ BED (10), the AUC value was 0.688 (95% CI = 0.500–0.876, $P = 0.068$) and cut-off value was >85 Gy (sensitivity 63.6%, specificity 73.3%). ROC curves for oropharyngeal cancer patients are described in Figure 3B. In the univariate analysis, the following values were significant; tumor size >2.5 cm, DOI >1.2 cm, $CTV_{p,max}/fx$ >2.3 Gy/fx, and $CTV_{p,max}$ BED (10) >85 Gy in Table 5. A DOI >1.2 cm (OR 21.499, $P = 0.005$) and $CTV_{p,max}/fx$ >2.3 Gy/fx (OR 12.972, $P = 0.021$) remained significant predictors of STN in multivariate analysis. Acute grade 3 mucositis showed a correlation with STN occurrence (OR 10.537, $P = 0.052$) (Table 3).

**DISCUSSION**

In this study, we evaluated STN in head and neck cancer patients treated with PORT after TORS and WE with primary closure. A total of 19% of the patients developed STN, and the soft tissue lesions and related pain were eventually improved by oral steroid and opioids. Deeper DOI (>1.2–1.4 cm) and higher $CTV_{p,max}/fx$ (>2.3 Gy/fx) were related to the occurrence of STN, which did not have an effect on local recurrence. Consistent risk factors for STN were observed in a subset analysis of the oropharyngeal cancer patients.

Lukens et al\(^8\) first described the significance of STN in patients treated with TORS and PORT, and they reported that DOI, total radiation dose to the resection bed and grade 3 acute mucositis were risk factors for developing STN. These authors were able to reduce the occurrence of STN after limiting the mucosal dose (negative margin: 60 Gy/30 fx; close: 63 Gy/30 fx; and positive: 66 Gy/30 fx), and although they indicated that careful radiation planning is required in patients treated with TORS, clear quantitative relationships were not reported between the mucosal dose and STN occurrence. Though the frequency of STN in our study was lower than the 28% in Lukens report, a similar maximal radiation dose per fraction and greater DOI were found to be important for the development of STN. Furthermore, we provide suggestions for the critical
TABLE 1. Patient and Treatment Characteristics of All Patients

| Characteristics                  | Overall (n = 67) | STN (n = 13) | No STN (n = 54) | P      |
|----------------------------------|-----------------|--------------|-----------------|--------|
| **Age (range)**                  | 59 (35–89)      | 59 (44–77)   | 59 (35–89)      | 0.28   |
| **Sex**                          |                 |              |                 |        |
| Male                             | 60 (10.4%)      | 10 (76.9%)   | 50 (92.6%)      | 0.127  |
| Female                           | 7 (89.6%)       | 3 (23.1%)    | 4 (7.4%)        |        |
| **Comorbidity**                  |                 |              |                 |        |
| Yes                              | 36 (53.7%)      | 11 (84.6%)   | 25 (46.3%)      | 0.013  |
| No                               | 31 (46.3%)      | 2 (15.4%)    | 29 (53.7%)      |        |
| **Site**                         |                 |              |                 |        |
| Oropharynx                       | 51 (76.1%)      | 12 (92.3%)   | 39 (72.2%)      | 0.088  |
| Hypopharynx                      | 5 (7.5%)        | 1 (7.7%)     | 4 (7.4%)        |        |
| Larynx                           | 9 (13.4%)       | 0 (0%)       | 9 (16.7%)       |        |
| Oral cavity                      | 2 (3.0%)        | 0 (0%)       | 2 (3.7%)        |        |
| **Smoking (1 missing)**          |                 |              |                 |        |
| Never                            | 28 (42.4%)      | 6 (50%)      | 22 (40.7%)      | 0.461  |
| Past                             | 36 (54.5%)      | 6 (50%)      | 30 (55.6%)      |        |
| Current                          | 2 (3%)          | 0 (1%)       | 2 (3.7%)        |        |
| **Pathologic T stage**           |                 |              |                 |        |
| 0                                | 3 (4.5%)        | 0 (0%)       | 3 (5.6%)        | 0.231  |
| 1                                | 32 (47.8%)      | 4 (30.8%)    | 28 (51.9%)      |        |
| 2                                | 22 (32.8%)      | 7 (53.8%)    | 15 (27.8%)      |        |
| 3                                | 9 (13.4%)       | 2 (15.4%)    | 7 (13.0%)       |        |
| 4                                | 1 (1.5%)        | 0 (0%)       | 1 (1.9%)        |        |
| **Pathologic T stage**           |                 |              |                 |        |
| p0–1                             | 35 (52.2%)      | 4 (30.8%)    | 31 (57.4%)      | 0.048  |
| p2–4                             | 32 (47.8%)      | 9 (69.2%)    | 23 (42.6%)      |        |
| **Primary tumor size**           |                 |              |                 |        |
| Median (range)                   | 2 cm (0.3–5.2)  | 2.8 cm (0.6–5.2) | 1.9 cm (0.3–5) | 0.174  |
| **Depth of invasion**            |                 |              |                 |        |
| Median (range)                   | 0.85 cm (0.15–2.7) | 1.7 cm (0.2–2.1) | 0.7 cm (0.15–2.7) | 0.003  |
| **Time interval, d**             |                 |              |                 |        |
| OP-RT start                      | 40 (22–89)      | 41 (22–48)   | 38 (28–89)      | 0.391  |
| RT duration                      | 44 (35–103)     | 42 (39–103)  | 44.3 (35–68)    | 0.441  |
| Total Tx time                    | 83 (70–131)     | 84 (73–125)  | 83 (70–131)     | 0.515  |
| **CCRT**                         |                 |              |                 |        |
| Yes                              | 41 (61.2%)      | 7 (53.8%)    | 34 (63%)        | 0.545  |
| No                               | 26 (38.8%)      | 6 (46.2%)    | 20 (37%)        |        |
| **RT modality**                  |                 |              |                 |        |
| 3D-CRT                           | 12 (17.9%)      | 1 (7.7%)     | 11 (20.4%)      | 0.435  |
| IMRT                             | 55 (82.1%)      | 12 (92.3%)   | 43 (79.6%)      |        |
| **RT field**                     |                 |              |                 |        |
| Direct                           | 57 (85.1%)      | 12 (92.3%)   | 45 (83.3%)      | 0.673  |
| Indirect                         | 10 (14.9%)      | 1 (7.7%)     | 9 (16.7%)       |        |
| **Highest grade of acute mucositis** |           |              |                 |        |
| 0–2                              | 41 (62.1%)      | 3 (25%)      | 38 (70.4%)      | 0.007  |
| 3                                | 25 (37.9%)      | 9 (75%)      | 16 (29.6%)      |        |
| CTVp, cc                         | 26.8 (7.1–105.4) | 24.8 (9.6–67.2) | 27.8 (7.1–105.4) | 0.503  |
| CTVp, mean, Gy                   | 64.5 (50.58–70.84) | 65.45 (52.05–69.02) | 64.3 (50.58–70.84) | 0.621  |
| CTVp, mean/fx, Gy/fx             | 2.07 (1.69–2.33) | 2.11 (1.93–2.3) | 2.06 (1.69–2.33) | 0.359  |
| CTVp,max, Gy                     | 68.2 (30.42–77.23) | 69.38 (62.64–76.34) | 67.85 (30.42–77.23) | 0.209  |
| CTVp,max/fx, Gy/fx               | 2.21 (1.01–2.54) | 2.3 (2.05–2.54) | 2.19 (1.01–2.49) | 0.038  |
| CTVp,max BED (10), Gy            | 78.06 (59.11–87.03) | 79.27 (62.08–84.90) | 77.64 (59.11–87.03) | 0.571  |
| CTVp,max BED (10), Gy            | 83.24 (33.5–96.47) | 85.16 (77.17–95.77) | 82.56 (33.50–96.47) | 0.135  |

3D-CRT = 3-dimensional conformal radiotherapy, BED (10) = biological equivalent doses using α/β = 10, CCRT = concurrent chemoradiotherapy, CTVp = clinical target volume of primary tumor bed, CTVp,max/fx = fraction size of CTVp,max, CTVp,max = maximum dose of CTVp, CTVp, mean/fx = fraction size of CTVp, mean, CTVp, mean = mean dose of CTVp, IMRT = intensity modulated radiotherapy, OP = operation, RT = radiotherapy, Tx = treatment.

Time interval means as follows; OP-RT start: from surgery to RT start, RT duration: from RT start to RT completion, total treatment duration: from surgery to RT completion.

Direct means RT delivered to primary tumor bed intentionally.
Dosimetric and pathologic values of STN patients. Higher CTVp_max/fx at >2.3 Gy/fx and greater DOI at >1.2 cm were significantly associated with STN. In oropharyngeal cancer patients, larger tumor of >2.5 cm also showed a significant effect on STN. The lower frequency of STN in our study may have been caused by a lower median total dose to the resection bed compared with that in Lukas’ study. In addition, the total dose calculated as BED (10) due to variable fractionation scheme was not related to the STN.

Radiation-induced mucosal injuries are healed during the regeneration process through surviving stem cells within the exposed area or migrating stem cells from untreated areas. Patients treated with TORS or WE without flap reconstruction may have fewer stem cells in the primary surgical bed. Furthermore, in cases with larger tumor and greater DOI, fewer stem cells may remain. In our study, greater DOI and larger tumor size correlated with STN. In addition, tumor size >2.5 cm and stage pT2–4 were significant in oropharyngeal cancer patients. We suggest that RT planning should be performed carefully for patients with larger tumors (>2.5 cm) and greater DOI (>1.2 cm) treated with TORS or WE with primary closure.

FIGURE 3. A receiver operator characteristic curves for (A) all patients and (B) oropharyngeal cancer patients, DOI = depth of invasion, CTVp_max/fx = fraction size of maximum total dose for primary tumor bed, BED (10) = biological equivalent doses using α/β = 10.
Comorbidities are risk factors for radiation-induced normal tissue injury. Hypertension and diabetes are highly correlated to radiation damage because they impair vascularity. In our study, the comorbidities were related to STN, with an STN incidence of 34.5% in patients with comorbidities and 9% in patients without comorbidities. HTN and diabetes were the most common comorbidities, and this result indirectly shows the relationship between STN and impaired vascularity.

STN is considered a consequential late effect (CLE), and the complexity and aggressiveness of treatment may have increase the CLE. In our study, the comorbidities were related to STN, with an STN incidence of 34.5% in patients with comorbidities and 9% in patients without comorbidities. HTN and diabetes were the most common comorbidities, and this result indirectly shows the relationship between STN and impaired vascularity.

STN is considered a consequential late effect (CLE), and the complexity and aggressiveness of treatment may have increase the CLE. The relationship of acute mucositis and CLE has been previously described in accelerated RT studies. To improve local control, accelerated RT schedule have been prescribed for the head and neck cancer patients. Acute mucositis were significantly higher in patients treated with accelerated RT compared with conventional RT. As prolonged severe acute mucosal reactions progressed to CLE, radiation necrosis developed in 22% of the accelerated RT group; however, after reducing the fraction size from 2 to 1.8 Gy/fx, further necrosis did not occur. In the PORT studies of patients with accelerated schedules, the authors also reported that at 1.8 Gy/fx, mucosal necrosis did not develop. According to these studies, the RT fraction size was important risk factor for developing STN. Similarly, our study showed that higher fraction size could increase STN occurrence even with conventional RT schedule.

Acute mucositis and CLE are known to be related to treatment time. However, in our study, treatment time did not affect STN. Significant differences were not observed for the OP to RT interval, RT duration, and overall treatment duration (OP plus RT) between patients with and without STN. RT was usually planned 4 to 6 weeks after surgery, and the total RT treatment lasted approximately 6 to 7 weeks. Therefore the time effect on the STN could not be discerned with this RT schedule. As in Lukas’ study, the treatment time could not be differentiated according to the STN occurrence.

An increasing number of studies have focused on complications related to TORS. Several studies have suggested that the contraindications of TORS and treatment outcomes of PORT after TORS are under evaluated. Disruptions of lymphovascular supply and injuries to the connective tissue, and reductions in stem cells in the surgical bed could result in unexpected complications after PORT. The surgical bed of TORS or WE with primary closure is poorly vascularized, and PORT induces further vasculature damage through the occlusion or loss of small vasculature and thrombotic formation, and we speculate that such damage may occur in the time interval between completion of RT and STN occurrence. To improve the therapeutic ratio, appropriate patients must be selected for TORS and risk factors of STN should be carefully reviewed in the planning of PORT.

Our study contained certain limitations. The direct comparison of STN occurrence results between patients with TORS or WE with primary closure and patients with reconstructive

### TABLE 2. Cut-Off Values as a Risk Factor of STN

| Variable | STN (%) | P      |
|----------|---------|--------|
| Depth of invasion (56 pts), cm |       |        |
| ≤1.4 | 11.1 | <0.001 |
| >1.4 | 72.7 |        |
| CTVpmax/fx (65 pts), Gy/fx |       |        |
| ≤2.3 | 12.0 | 0.022  |
| >2.3 | 37.5 |        |

CTVp = clinical target volume of primary tumor bed, fx = fraction, max = maximum, STN = soft tissue necrosis.

### TABLE 3. Multivariate Analysis for STN

| Variable | Odds Ratio | 95% CI | P      |
|----------|------------|--------|--------|
| All patients |            |        |        |
| Depth of invasion, cm |       |        |        |
| >1.4 | 14.04 | 2.313–85.230 | 0.004  |
| ≤1.4 | 1        |        |        |
| CTVpmax/fx, Gy/fx |       |        |        |
| >2.3 | 6.344 | 1.058–38.026 | 0.043  |
| ≤2.3 | 1        |        |        |
| Acute mucositis |       |        |        |
| Grade 0–2 | 6.090 | 0.970–38.223 | 0.054  |
| Grade 3 | 1        |        |        |
| Oropharyngeal cancer |       |        |        |
| Depth of invasion, cm |       |        |        |
| >1.2 | 21.499 | 2.486–185.903 | 0.005  |
| ≤1.2 | 1        |        |        |
| CTVpmax/fx, Gy/fx |       |        |        |
| >2.3 | 12.972 | 1.463–114.990 | 0.021  |
| ≤2.3 | 1        |        |        |
| Acute mucositis |       |        |        |
| Grade 0–2 | 10.537 | 0.977–113.640 | 0.052  |
| Grade 3 | 1        |        |        |

CI = confidence interval, CTVp = clinical target volume of primary tumor bed, fx = fraction, max = maximum, STN = soft tissue necrosis.
### TABLE 4. Patient and Treatment Characteristics of Oropharyngeal Cancer Patients

| Characteristics                  | Overall (n = 51) | STN (n = 12) | No STN (n = 39) | P     |
|----------------------------------|------------------|--------------|-----------------|-------|
| Age (range)                      | 59 (35–89)       | 57.5 (44–77) | 59 (35–89)      | 0.398 |
| Sex                              |                  |              |                 |       |
| Male                             | 45 (88.2%)       | 9 (75%)      | 36 (92.3%)      | 0.13  |
| Female                           | 6 (11.8%)        | 3 (25%)      | 3 (7.7%)        |       |
| Comorbidities                    |                  |              |                 |       |
| Yes                              | 29 (56.9%)       | 10 (83.3%)   | 19 (48.7%)      | 0.034 |
| No                               | 22 (43.1%)       | 2 (16.7%)    | 20 (51.3%)      |       |
| Site                             |                  |              |                 |       |
| Tonsillar                        | 43 (84.3%)       | 10 (83.3%)   | 33 (84.6%)      | 0.812 |
| Base of tongue                   | 6 (11.8%)        | 2 (16.7%)    | 4 (10.3%)       |       |
| Soft palate                      | 2 (3.9%)         | 4 (10.3%)    | 2 (5.1%)        |       |
| Smoking                          |                  |              |                 |       |
| Never                            | 25 (50%)         | 6 (54.5%)    | 19 (48.7%)      | 0.579 |
| Past                             | 23 (46%)         | 5 (45.5%)    | 18 (46.2%)      |       |
| Current                          | 2 (4%)           | 0 (0%)       | 2 (5.1%)        |       |
| HPV                              |                  |              |                 |       |
| Negative                         | 9 (22.5%)        | 3 (25.0%)    | 6 (21.4%)       | 1.00  |
| Positive                         | 31 (77.5%)       | 9 (75.0%)    | 22 (78.6%)      |       |
| Pathologic T stage               |                  |              |                 |       |
| p0–1                             | 29 (56.9%)       | 4 (33.3%)    | 25 (64.1%)      | 0.06  |
| p2–4                             | 22 (43.1%)       | 8 (66.7%)    | 14 (35.9%)      |       |
| Tumor size                       |                  |              |                 |       |
| Median (range)                   | 1.8 (0.3–5.2)    | 2.9 (0.6–5.2)| 1.7 (0.3–5.0)   | 0.087 |
| Depth of invasion                |                  |              |                 |       |
| Median (range)                   | 0.9 (0.15–2.7)   | 1.75 (0.2–2.1)| 0.7 (0.15–2.7) | 0.002 |
| CCRT                             |                  |              |                 |       |
| Yes                              | 30 (58.8%)       | 6 (50%)      | 24 (61.5%)      | 0.518 |
| No                               | 21 (41.2%)       | 6 (50%)      | 15 (38.5%)      |       |
| RT modality                      |                  |              |                 |       |
| 3D-CRT                           | 8 (15.7%)        | 0 (0%)       | 8 (20.5%)       | 0.173 |
| IMRT                             | 43 (84.3%)       | 12 (100%)    | 31 (79.5%)      |       |
| Time interval, d*                |                  |              |                 |       |
| OP-RT start                      | 38 (22–57)       | 41 (22–48)   | 38 (28–57)      | 0.344 |
| RT duration                      | 43 (35–103)      | 42 (39–103)  | 44 (35–61)      | 0.455 |
| Total Tx time                    | 83 (70–125)      | 83.5 (73–125)| 83 (70–104)     | 0.456 |
| RT field                        |                  |              |                 |       |
| Direct                           | 45 (88.2%)       | 11 (91.7%)   | 34 (87.2%)      | 1     |
| Indirect                         | 6 (11.8%)        | 1 (8.3%)     | 5 (12.8%)       |       |
| Highest grade of acute mucositis |                  |              |                 |       |
| 0–2                              | 27 (54%)         | 3 (27.3%)    | 24 (61.5%)      | 0.044 |
| 3                                | 23 (46%)         | 8 (72.7%)    | 15 (38.5%)      |       |
| CTV, cc                          | 25 (7.1–105.4)   | 25.75 (9.6–67.2)| 24.60 (7.1–105.4)| 0.801 |
| CTV, mean, Gy                    | 64.05 (50.58–70.02)| 66.01 (52.05–69.02)| 63.75 (50.58–70.02)| 0.294 |
| CTV, mean/fx, Gy/fx              | 2.07 (1.69–2.33) | 2.12 (1.93–2.30)| 2.06 (1.69–2.33)| 0.208 |
| CTV, max, Gy                     | 68.58 (54.21–76.34)| 69.64 (62.64–76.34)| 68.0 (54.21–73.60)| 0.137 |
| CTV, max/fx, Gy/fx               | 2.23 (1.81–2.54) | 2.30 (2.11–2.54)| 2.20 (1.81–2.43)| 0.028 |
| CTV, mean BED (10), Gy           | 77.50 (59.11–86.36)| 80.32 (62.08–84.90)| 76.85 (59.11–86.36)| 0.228 |
| CTV, max BED (10), Gy            | 83.70 (64.01–95.77)| 85.28 (77.17–95.77)| 83.07 (64.01–91.07)| 0.085 |

3D-CRT = 3-dimensional conformal radiotherapy, BED (10) = biological equivalent doses using α/β = 10, CCRT = concurrent chemoradiotherapy, CTVp = clinical target volume of primary tumor bed, CTVp/mean/fx = fraction size of CTVp mean, CTVp max = maximum dose of CTVp, CTVp max/fx = fraction size of CTVp mean, CTVp mean = mean dose of CTVp, HPV = human papilloma virus, IMRT = intensity modulated radiotherapy, OP = operation, RT = radiotherapy, Tx = treatment.

*Time interval means as follows; OP-RT start: from surgery to RT start, RT duration: from RT start to RT completion, total treatment duration: from surgery to RT completion.

†Direct means RT delivered to primary tumor bed intentionally.
surgery were not provided. Additionally, biopsy specimens were not collected in all STN cases, which limited our ability to explain the pathophysiologic mechanisms of STN occurrence.

As minimal invasive treatment, TORS has showed the promising treatment result and its indication has been extended. STN related TORS and PORT is a complication to be managed, but the morbidity of treatment could be worse. The STN related TORS and PORT is a complication to be managed.

In conclusion, patients treated with TORS or WE with primary closure followed by PORT had a high risk of surgical bed STN. The risk factors of STN determined from the multivariate analysis included greater DOI (1.2–1.4 cm) and higher CTVp max BED (10), Gy. STN was not related to local recurrence. RT plans after TORS must be carefully designed to prevent STN, and maximal fractional dose to the surgical bed above 2.3 Gy should be avoided. The surgical bed must be contoured, even when only irradiating the neck lymphatics and the actual RT dose delivered to the surgical bed should be evaluated.

REFERENCES

1. Weinstein GS, O’Malley BW Jr, Magnuson JS, et al. Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope. 2012;122:1701–1707.

2. Kelly K, Johnson-Obasiki S, Luningu I, et al. Oncologic, functional and surgical outcomes of primary Transoral Robotic Surgery for early squamous cell carcinoma of the oropharynx: a systematic review. Oral Oncol. 2014;50:696–703.

3. Lorincz BB, Mockelmann N, Busch CJ, et al. Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck. 2015;37:1618–1624.

4. Dziegielewski PT, Teknos TN, Durmus K, et al. Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg. 2013;139:1099–1108.

5. Lorincz BB, Busch CJ, Mockelmann N, et al. Feasibility and safety of transoral robotic surgery (TORS) for early hypopharyngeal cancer: a subset analysis of the Hamburg University TORS-trial. Eur Arch Otorhinolaryngol. 2015;272:2993–2998.

6. Carpenter TJ, Kann B, Buckstein MH, et al. Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2014;123:791–797.

7. Huang SH, Hansen A, Rathod S, et al. Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer: the radiation oncologist’s and medical oncologist’s perspectives. Curr Opin Otolaryngol Head Neck Surg. 2015;23:139–147.

8. Lukens JN, Lin A, Gamerman V, et al. Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:981–988.

9. Weinstein GS, O’Malley BW Jr, Rinaldo A, et al. Understanding contraindications for transoral robotic surgery (TORS) for oropharyngeal cancer. Eur Arch Otorhinolaryngol. 2015;272:1551–1552.

10. Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat Oncol J. 2014;32:103–115.

11. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–850.

12. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35.

13. Stone HB, Coleman CN, Anscher MS, et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4:529–536.

14. Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist. 2002;7:136–143.

15. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999;52:157–164.

16. Składowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:706–713.

17. Suwinski R, Bankowska-Woźniak M, Majewski W, et al. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions. Radiother Oncol. 2005;77:58–64.

18. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61:223–231.

19. Dorr W. Radiobiology of tissue reactions. Ann ICRP. 2015;44:58–68.

---

**TABLE 5. Cut-Off Values as a Risk Factor of STN for Oropharyngeal Cancer Patients**

| Variable | STN (%) | P       |
|----------|---------|---------|
| Primary tumor size (47 pts) |         |         |
| ≤2.5     | 15.6    | 0.034   |
| >2.5     | 46.7    |         |
| Depth of invasion, cm |         |         |
| ≤1.2     | 10.7    | 0.001   |
| >1.2     | 64.3    |         |
| CTVp max BED (10), Gy |         |         |
| ≤85      | 12.9    | 0.047   |
| >85      | 36.8    |         |
| CTVp max/fx, Gy/fx |         |         |
| ≤2.3     | 13.2    | 0.007   |
| >2.3     | 50.0    |         |

**Notes:**
- BED (10) = biological equivalent doses using α/β = 10.
- CTVp = clinical target volume of primary tumor bed, fx = fraction,
  max = maximum, STN = soft tissue necrosis.